NCT02834013 2026-03-18Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting818 enrolled
NCT05112601 2026-03-18Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaNational Cancer Institute (NCI)Phase 2 Recruiting81 enrolled
NCT03875820 2026-03-10FRAMEInstitute of Cancer Research, United KingdomPhase 1 Active not recruiting87 enrolled
NCT04065269 2026-02-20ATARIInstitute of Cancer Research, United KingdomPhase 2 Active not recruiting174 enrolled